Humira’s list price is approximately $6,923 for a standard two-pen carton, which covers one month of treatment for most conditions. What you actually pay, though, depends almost entirely on your insurance, your plan type, and whether you use a savings program or switch to a biosimilar. Many patients pay $0 to $5 per month, while others face bills in the thousands.
The List Price vs. What Patients Actually Pay
AbbVie’s current wholesale acquisition cost for a two-pen pack of Humira (40 mg each) is $6,922.62. For the standard dosing schedule of one injection every other week, that two-pen carton is a full month’s supply. Some conditions require weekly injections after an initial loading period, which would double the monthly cost at list price.
Almost nobody pays that full amount. Insurance negotiations, manufacturer discounts, and assistance programs all sit between the list price and your actual bill. But the list price matters because it determines what you owe during high-deductible periods and shapes your coinsurance percentages.
Cost With Commercial Insurance
If you have employer-sponsored or marketplace insurance, your monthly cost for Humira typically falls into one of two scenarios. With a traditional copay plan, you might owe a flat specialty-tier copay, often $50 to $150 per fill. With a coinsurance plan, you pay a percentage of the negotiated price, which can mean several hundred dollars or more per month, especially early in the year before you’ve met your deductible.
High-deductible plans hit hardest at the start of each calendar year. Until you meet your deductible, you may be responsible for the full negotiated rate your insurer arranged with the pharmacy, which can still run into the thousands for a single fill. Once you clear the deductible, coinsurance kicks in, and once you hit your plan’s out-of-pocket maximum, the plan covers the rest for the year.
The Humira Savings Card
AbbVie offers a copay assistance program through its “Complete” savings card that can reduce your cost to as little as $0 per month, with a maximum annual benefit that has historically been around $14,000. This card is available to patients with commercial insurance and covers copays, coinsurance, and sometimes deductible costs. It does not apply to government-funded insurance like Medicare, Medicaid, or Tricare.
If you have commercial insurance, this savings card is worth applying for before your first fill. It can effectively eliminate your out-of-pocket cost for most of the year, though patients on very high-deductible plans may exhaust the annual benefit before December.
Cost With Medicare Part D
Medicare patients face a different cost structure. Part D plans can charge a deductible of up to $615 (in 2026), which you pay out of pocket before coverage begins. After meeting the deductible, you enter the initial coverage stage and typically pay 25% coinsurance on brand-name drugs. For a medication with Humira’s price, that 25% adds up quickly.
The good news: once your total out-of-pocket spending on Part D drugs reaches $2,100 (in 2026), you enter catastrophic coverage and pay nothing for covered prescriptions for the rest of the calendar year. For Humira patients, this threshold is often reached within the first few months, meaning you may face significant costs in January and February but pay $0 from spring onward. The manufacturer’s copay card cannot be used with Medicare, but the $2,000 annual out-of-pocket cap that took effect in 2025 has substantially reduced total yearly costs for Medicare enrollees on expensive specialty drugs.
Cost Without Insurance
Paying cash at a retail pharmacy without any insurance or discount program means facing something close to the full list price: roughly $6,900 or more per month. This is rarely the best option, because alternatives exist even for uninsured patients.
AbbVie’s myAbbVie Assist program provides Humira at no cost to patients with limited or no insurance who meet income requirements. For 2026, a single-person household must earn $63,840 or less, a two-person household $86,560 or less, and a four-person household $132,000 or less. Each additional family member raises the threshold by $22,720. Patients whose commercial insurance plans require applying to this program as a condition of coverage are not eligible.
Biosimilars Can Cut the Price Dramatically
Since 2023, several biosimilars (near-identical versions of Humira) have entered the U.S. market. These alternatives generally cost 50% to 80% less than Humira’s list price. One biosimilar, adalimumab-adbm, is available through a GoodRx partnership at $550 for a two-pack, representing a 92% discount from Humira’s list price. That brings the monthly cost for a standard every-other-week dosing schedule to around $550 without insurance.
Biosimilars work the same way as the original drug and are approved by the FDA for the same conditions. Your prescriber can switch you to a biosimilar, and many insurance plans now prefer or require biosimilars because of the lower cost. If your plan still covers brand-name Humira, the copay may be higher than for a biosimilar alternative. It’s worth asking your pharmacist or insurer which adalimumab product has the lowest cost on your specific plan.
How Dosing Affects Your Monthly Bill
The standard Humira dose for most conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, is 40 mg every other week. That means two pens per month and one carton per fill.
For plaque psoriasis and certain eye conditions, the regimen starts with a higher loading dose (80 mg initially) before settling into the every-other-week schedule. Some patients with Crohn’s disease or ulcerative colitis may need weekly injections, doubling the monthly supply to four pens and roughly doubling the cost at every level, from list price down to copays. If your prescriber has you on a weekly schedule, factor in the higher quantity when evaluating savings programs and annual benefit caps.
Practical Ways to Lower Your Cost
- Use the savings card first. If you have commercial insurance, AbbVie’s copay card can bring your cost to $0 per month for most of the year.
- Ask about biosimilars. Switching to a biosimilar can reduce both your plan’s cost and your copay, especially if your insurer places biosimilars on a lower formulary tier.
- Apply for patient assistance. Uninsured or underinsured patients who meet income thresholds can receive the medication for free through myAbbVie Assist.
- Check specialty pharmacy pricing. Your insurer may require you to use a specific specialty pharmacy, but if you have flexibility, prices vary. Discount platforms sometimes offer biosimilars at steep markdowns.
- Time your refills strategically on Medicare. Because Part D’s out-of-pocket cap resets each January, filling a 90-day supply early in the year (if your plan allows it) can help you reach catastrophic coverage faster and spend less overall.